{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T15:22:13Z","timestamp":1761578533954},"reference-count":10,"publisher":"Medical Association of Nippon Medical School","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nippon Med Sch"],"published-print":{"date-parts":[[2009]]},"DOI":"10.1272\/jnms.76.4","type":"journal-article","created":{"date-parts":[[2009,3,19]],"date-time":"2009-03-19T06:04:43Z","timestamp":1237442683000},"page":"4-8","source":"Crossref","is-referenced-by-count":17,"title":["Drug-Induced Interstitial Lung Diseases Associated with Molecular-Targeted Anticancer Agents"],"prefix":"10.1272","volume":"76","author":[{"given":"Akihiko","family":"Gemma","sequence":"first","affiliation":[{"name":"Division of Pulmonary Medicine, Infection Diseases and Oncology, Graduate School of Medicine, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"21","reference":[{"key":"1","unstructured":"1. Final report of the expert committee on acute lung diseases\/interstitial pneumonia due to gefitinib (Irresa<sup>&reg;<\/sup> Tablets 250), AstraZeneca, March 2003."},{"key":"2","unstructured":"2. \"Results and discussion of the prospective survey on the use of Irresa<sup>&reg;<\/sup> Tablets 250 (Special survey)\", AstraZeneca, August 2004."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Kudoh S, Kato H, Nishiwaki Y, et al.: Japan Thoracic Radiology Group Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med 2008; 177: 1348-1357.","DOI":"10.1164\/rccm.200710-1501OC"},{"key":"4","unstructured":"4. Gemma A: Special article \"The science of adverse reaction\": II Outline of adverse reaction; 14) anticancer agents; d) interstitial pneumonia [in Japanese]. Jap J Clin Med (Nihon Rinsyo) 2007; 65 (Supple 8): 299-303."},{"key":"5","unstructured":"5. Gemma A: Lung diseases due to anti-malignant tumor agents [in Japanese]. Clin Oncology (Shuyo Naika) 2007; 1: 177-183."},{"key":"6","unstructured":"6. Instruction for appropriate use of Tarceba<sup>&reg;<\/sup> Tablets. Chugai Pharmaceutical."},{"key":"7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-11-4541"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Gotoh A, Ohyashiki K, Oshimi K, et al.: Lung injury associated with bortezomib therapy in relapsed\/refractory multiple myeloma in Japan: a questionnaire-based report from the \"lung injury by bortezomib\" joint committee of the Japanese society of hematology and the Japanese society of clinical hematology. Int J Hematol 2006; 84: 406-412.","DOI":"10.1532\/IJH97.06142"},{"key":"9","unstructured":"9. Instruction for appropriate use of Velcade<sup>&reg;<\/sup>. Janssen Pharmaceutical, 2006."},{"key":"10","unstructured":"10. Interim report on clinical studies of Velcade<sup>&reg;<\/sup> Injection 3 mg. Janssen Pharmaceutical, 2007."}],"container-title":["Journal of Nippon Medical School"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.jstage.jst.go.jp\/article\/jnms\/76\/1\/76_1_4\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T07:42:02Z","timestamp":1617003722000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jstage.jst.go.jp\/article\/jnms\/76\/1\/76_1_4\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1272\/jnms.76.4","relation":{},"ISSN":["1345-4676","1347-3409"],"issn-type":[{"value":"1345-4676","type":"print"},{"value":"1347-3409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009]]}}}